Cargando…
Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial
BACKGROUND: The Paramedic Acute Stroke Treatment Assessment (PASTA) trial evaluated an enhanced emergency care pathway which aimed to facilitate thrombolysis in hospital. A pre-planned health economic evaluation was included. The main results showed no statistical evidence of a difference in either...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864331/ https://www.ncbi.nlm.nih.gov/pubmed/33724103 http://dx.doi.org/10.1177/17474930211006302 |
_version_ | 1784655442908020736 |
---|---|
author | Bhattarai, Nawaraj Price, Christopher I McMeekin, Peter Javanbakht, Mehdi Vale, Luke Ford, Gary A Shaw, Lisa |
author_facet | Bhattarai, Nawaraj Price, Christopher I McMeekin, Peter Javanbakht, Mehdi Vale, Luke Ford, Gary A Shaw, Lisa |
author_sort | Bhattarai, Nawaraj |
collection | PubMed |
description | BACKGROUND: The Paramedic Acute Stroke Treatment Assessment (PASTA) trial evaluated an enhanced emergency care pathway which aimed to facilitate thrombolysis in hospital. A pre-planned health economic evaluation was included. The main results showed no statistical evidence of a difference in either thrombolysis volume (primary outcome) or 90-day dependency. However, counter-intuitive findings were observed with the intervention group showing fewer thrombolysis treatments but less dependency. AIMS: Cost-effectiveness of the PASTA intervention was examined relative to standard care. METHODS: A within trial cost-utility analysis estimated mean costs and quality-adjusted life years over 90 days’ time horizon. Costs were derived from resource utilization data for individual trial participants. Quality-adjusted life years were calculated by mapping modified Rankin scale scores to EQ-5D-3L utility tariffs. A post-hoc subgroup analysis examined cost-effectiveness when trial hospitals were divided into compliant and non-compliant with recommendations for a stroke specialist thrombolysis rota. RESULTS: The trial enrolled 1214 patients: 500 PASTA and 714 standard care. There was no evidence of a quality-adjusted life year difference between groups [0·007 (95% CI: −0·003 to 0·018)] but costs were lower in the PASTA group [−£1473 (95% CI: −£2736 to −£219)]. There was over 97.5% chance that the PASTA pathway would be considered cost-effective. There was no evidence of a difference in costs at seven thrombolysis rota compliant hospitals but costs at eight non-complaint hospitals costs were lower in PASTA with more dominant cost-effectiveness. CONCLUSIONS: Analyses indicate that the PASTA pathway may be considered cost-effective, particularly if deployed in areas where stroke specialist availability is limited. Trial Registration: ISRCTN12418919 www.isrctn.com/ISRCTN12418919 |
format | Online Article Text |
id | pubmed-8864331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-88643312022-02-24 Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial Bhattarai, Nawaraj Price, Christopher I McMeekin, Peter Javanbakht, Mehdi Vale, Luke Ford, Gary A Shaw, Lisa Int J Stroke Research BACKGROUND: The Paramedic Acute Stroke Treatment Assessment (PASTA) trial evaluated an enhanced emergency care pathway which aimed to facilitate thrombolysis in hospital. A pre-planned health economic evaluation was included. The main results showed no statistical evidence of a difference in either thrombolysis volume (primary outcome) or 90-day dependency. However, counter-intuitive findings were observed with the intervention group showing fewer thrombolysis treatments but less dependency. AIMS: Cost-effectiveness of the PASTA intervention was examined relative to standard care. METHODS: A within trial cost-utility analysis estimated mean costs and quality-adjusted life years over 90 days’ time horizon. Costs were derived from resource utilization data for individual trial participants. Quality-adjusted life years were calculated by mapping modified Rankin scale scores to EQ-5D-3L utility tariffs. A post-hoc subgroup analysis examined cost-effectiveness when trial hospitals were divided into compliant and non-compliant with recommendations for a stroke specialist thrombolysis rota. RESULTS: The trial enrolled 1214 patients: 500 PASTA and 714 standard care. There was no evidence of a quality-adjusted life year difference between groups [0·007 (95% CI: −0·003 to 0·018)] but costs were lower in the PASTA group [−£1473 (95% CI: −£2736 to −£219)]. There was over 97.5% chance that the PASTA pathway would be considered cost-effective. There was no evidence of a difference in costs at seven thrombolysis rota compliant hospitals but costs at eight non-complaint hospitals costs were lower in PASTA with more dominant cost-effectiveness. CONCLUSIONS: Analyses indicate that the PASTA pathway may be considered cost-effective, particularly if deployed in areas where stroke specialist availability is limited. Trial Registration: ISRCTN12418919 www.isrctn.com/ISRCTN12418919 SAGE Publications 2021-04-07 2022-03 /pmc/articles/PMC8864331/ /pubmed/33724103 http://dx.doi.org/10.1177/17474930211006302 Text en © 2021 World Stroke Organization https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Bhattarai, Nawaraj Price, Christopher I McMeekin, Peter Javanbakht, Mehdi Vale, Luke Ford, Gary A Shaw, Lisa Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial |
title | Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment
Assessment (PASTA) during emergency stroke care: Economic results from a
pragmatic cluster randomized trial |
title_full | Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment
Assessment (PASTA) during emergency stroke care: Economic results from a
pragmatic cluster randomized trial |
title_fullStr | Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment
Assessment (PASTA) during emergency stroke care: Economic results from a
pragmatic cluster randomized trial |
title_full_unstemmed | Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment
Assessment (PASTA) during emergency stroke care: Economic results from a
pragmatic cluster randomized trial |
title_short | Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment
Assessment (PASTA) during emergency stroke care: Economic results from a
pragmatic cluster randomized trial |
title_sort | cost-effectiveness of an enhanced paramedic acute stroke treatment
assessment (pasta) during emergency stroke care: economic results from a
pragmatic cluster randomized trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864331/ https://www.ncbi.nlm.nih.gov/pubmed/33724103 http://dx.doi.org/10.1177/17474930211006302 |
work_keys_str_mv | AT bhattarainawaraj costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial AT pricechristopheri costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial AT mcmeekinpeter costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial AT javanbakhtmehdi costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial AT valeluke costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial AT fordgarya costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial AT shawlisa costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial |